Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.来源:Barrons发布于 2026-10-29Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.相关标的:GILD继续访问返回新闻本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。